{"id":197963,"date":"2024-10-19T12:36:14","date_gmt":"2024-10-19T12:36:14","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/aami-10993-3-2014\/"},"modified":"2024-10-25T05:09:31","modified_gmt":"2024-10-25T05:09:31","slug":"aami-10993-3-2014","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/aami\/aami-10993-3-2014\/","title":{"rendered":"AAMI 10993 3 2014"},"content":{"rendered":"
Specifies strategies for hazard identification and tests on medical devices for genotoxicity, carcinogenicity, and reproductive and developmental toxicity. Applicable when the need to evaluate a medical device for potential genotoxicity, carcinogenicity, or reproductive toxicity has been established<\/p>\n
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
1<\/td>\n | ANSI\/AAMI\/ISO 10993-3:2014, Biological evaluation of medical devices\u2014Part 3: Tests for genotoxicity, carcinogenicity, and reproductive toxicity <\/td>\n<\/tr>\n | ||||||
3<\/td>\n | Title page <\/td>\n<\/tr>\n | ||||||
4<\/td>\n | AAMI Standard Copyright information <\/td>\n<\/tr>\n | ||||||
5<\/td>\n | Contents <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Glossary of equivalent standards <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Committee representation <\/td>\n<\/tr>\n | ||||||
10<\/td>\n | Background of ANSI\/AAMI adoption of ISO 10993-3:2014 <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | Introduction Introduction <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 1 Scope 2 Normative references <\/td>\n<\/tr>\n | ||||||
16<\/td>\n | 3 Terms and definitions 4 Requirements for test strategies 4.1 General <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 4.2 Additional requirements for carcinogenicity testing 4.3 Additional requirements for reproductive toxicity testing <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 5 Genotoxicity tests 5.1 General 5.2 Test strategy 5.2.1 General 5.2.2 Test battery <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 5.2.3 Follow-up evaluation <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | 5.3 Sample preparation <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | 6 Carcinogenicity tests 6.1 General 6.2 Evaluation strategy <\/td>\n<\/tr>\n | ||||||
22<\/td>\n | 6.3 Sample preparation 6.4 Test methods <\/td>\n<\/tr>\n | ||||||
23<\/td>\n | 7 Reproductive and developmental toxicity tests 7.1 General 7.2 Test strategy <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | 7.3 Sample preparation 7.4 Test methods 8 Test report <\/td>\n<\/tr>\n | ||||||
26<\/td>\n | Annex A: Guidance on selecting an appropriate sample preparation procedure in genotoxicity testing A.1 General <\/td>\n<\/tr>\n | ||||||
27<\/td>\n | A.2 Device materials A.2.1 Low Molecular Weight Chemicals (LMWC) A.2.2 Polymers (including naturally occurring polymers) A.2.2.1 LMWC contained in polymers A.2.2.2 Oligomers <\/td>\n<\/tr>\n | ||||||
28<\/td>\n | A.2.2.3 Biodegradable polymers A.2.3 Inorganic materials: Wear debris from metals, alloys and ceramics A.3 Sample Preparation Methods A.3.1 General <\/td>\n<\/tr>\n | ||||||
29<\/td>\n | Figure A.1 \u2014 Structured approach to select a sample preparation procedure <\/td>\n<\/tr>\n | ||||||
30<\/td>\n | Table A.1 \u2014 Common extraction solvents A.3.2 Method A A.3.3 Method B A.3.3.1 General <\/td>\n<\/tr>\n | ||||||
31<\/td>\n | A.3.3.2 Test sample preparation A.3.3.3 Procedure <\/td>\n<\/tr>\n | ||||||
32<\/td>\n | A.3.3.4 Expression of results A.3.4 Method C A.3.4.1 General A.3.4.2 Procedure <\/td>\n<\/tr>\n | ||||||
33<\/td>\n | A.4 Additional guidance on special sample preparation procedures A.4.1 Biodegradable polymers A.4.2 Inorganic materials: Wear debris from metals, alloys and ceramics A.4.3 LMWC <\/td>\n<\/tr>\n | ||||||
34<\/td>\n | Annex B: Flowchart for follow-up evaluation Figure B.1 \u2014 Flowchart for follow-up evaluation <\/td>\n<\/tr>\n | ||||||
35<\/td>\n | Annex C: Rationale of test systems C.1 Genotoxicity tests <\/td>\n<\/tr>\n | ||||||
36<\/td>\n | C.2 Carcinogenicity tests C.3 Reproductive\/developmental toxicity tests <\/td>\n<\/tr>\n | ||||||
37<\/td>\n | Annex D: Cell transformation test systems <\/td>\n<\/tr>\n | ||||||
38<\/td>\n | Annex E: Considerations for carcinogenicity studies performed as implantation studies E.1 Foreign body carcinogenesis E.2 Animal welfare considerations <\/td>\n<\/tr>\n | ||||||
39<\/td>\n | Annex F: In vitro tests for embryo toxicity Table F.1 \u2014 Criteria defined by the management team of the study to evaluate test performance <\/td>\n<\/tr>\n | ||||||
40<\/td>\n | Table F.2 \u2014 Summary of the classification results (all data[88]) <\/td>\n<\/tr>\n | ||||||
41<\/td>\n | Annex ZA: Relationship between this European Standard and the Essential Requirements of EU Directive 93\/42 EEC on medical devices Table ZA.1 \u2014 Correspondence between this European Standard and Directive 93\/42\/EEC on medical devices <\/td>\n<\/tr>\n | ||||||
43<\/td>\n | Annex ZB: Relationship between this European Standard and the Essential Requirements of EU Directive 90\/385\/EEC on active implantable medical devices Table ZB.1 \u2014 Correspondence between this European Standard and Directive 90\/385\/EEC on active implantable medical devices <\/td>\n<\/tr>\n | ||||||
44<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" ANSI\/AAMI\/ISO 10993-3:2014 – Biological evaluation of medical devices-Part 3: Tests for genotoxicity, carcinogenicity, and reproductive toxicity<\/b><\/p>\n |